Developer of Molecular Targeted and Immune Anti-Tumor Drugs

Covalent Drug Developer
▎Armstrong
On November 18, 2026, the clinical trial application for BeOne’s TER-2013 tablets was accepted by the NMPA.

TER-2013 is the world’s first selective AKT1 inhibitor, developed by Terremoto Biosciences, with its global Phase 1/2 clinical trial having been initiated in September 2025.

In April this year, Terremoto Biosciences announced the completion of a $108 million Series C financing round, with BeOne participating in this round of funding.


Terremoto Biosciences, founded in 2022, focuses on the development of lysine-targeted covalent inhibitors. Previous covalent drugs have mostly targeted cysteine residues due to their high reactivity; however, the scarcity of cysteine in proteins limits the number of available targets. In contrast, lysine is more abundant in proteins but exhibits inherently low reactivity. Terremoto Biosciences has established a technological platform for lysine-targeted covalent inhibitors, upon which it has built its research and development pipeline.

In November 2024, Terremoto Biosciences published a research article on AKT1-selective inhibitors in the journal Nature.AKT1 as a Disease-Driver Gene


In in vivo tumor models, this AKT1-selective inhibitor demonstrates superior antitumor activity without causing side effects such as hyperglycemia.

Summary
Based on the filing details, BeOne may have entered into a pipeline collaboration with Terremoto Biosciences during its investment process, acquiring the Chinese rights to Terremoto’s AKT1-selective inhibitor; specific terms are subject to official announcements.

Armstrong Technology Comprehensive Review Series
Comprehensive Review of Complement-Targeted Drug Technologies;
Complement Therapeutics: A Key Direction in Ophthalmic Treatment;
The Industry Knows Best the Temperature of Target Therapeutics;
A Comprehensive Overview of Bispecific Antibody Technology in China;